The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Does anybody know when the results would be due?
Here come the herd.
The interim results last year were on 26th September so they are due any day now. Will they hold them back until this matter is resolved? If they still release them then it will get even more interesting.
Be interesting to see if there are any late big deals posted after trading ceases for the day.
You would think this has got to explode at some point. IMHO I expect the new share price "home" to level out around 15p until more news hits.
Morning Jambon and co. It’s good you have you back Jambon.
I've invested here and in it for the long term. My previous thoughts were that we won't have any news until FLFL buy their final 5% of the company and being that the final 5% is something based on the average finished share price for the last 3 months (or something near to that description) then they wouldn't buy until another couple of months time as then they would get it for circa 10p. These hefty big buys in the last couple of hours along with some other hefty buys earlier in the week suggests maybe somebody/some people know something we don't yet and the final 5% buy in could be around the corner and earlier than previously thought. It's not what you know it's who you know! Once the final 5% buy in has been done then hopefully Koovs can start to communicate to us along with a forward looking statement and away we go.
Volume to increase when America and Canada wake up and want a piece of the action.
EyeGuy, I can tell you're genuine and spot on so far therefore thank you for your views and information. You believe 20p-30p easily. Can I please ask how long you believe it will take to get to this area of SP and also you say 20p-30p easily therefore short term, say up until the end of September, what do you currently for see the share price to be then? Thank you in advance if you reply.
I first noticed that we'd had an RNS when looking at Vox Markets share app but just realised that the RNS hasn't been put onto LSE's FARN Live RNS page. Thoughts anyone? Maybe not everybody knows about the RNS yet. IMO it's all about the late trades this afternoon although I struggled to buy just £850.00 worth of shares yesterday morning at 110p.
I remember reading a day or so on here that somebody had confirmation from FARN that they would be discussing Japan results tomorrow.
Thanks Dan1Nat1 as that’s a very interesting theory and totally agree Manifesto that the Japan trial would have been very carefully executed.
Old news I know but just think if the poor results were initially due to an administration error plus the Japanese trial results are a success#name your share price!
Not long to go all until we find out.
One of the theories behind Faron Pharmaceuticals’ (FARN:AIM) shocking trial failure earlier this week is that an active version of its Traumakine drug may not have been administered to patients.
Shares in Faron plummeted over 80% following its Phase III trial failure on Tuesday.
‘If no Traumakine was delivered, then the INTEREST trial didn’t show that Traumakine didn’t work as the active drug wasn’t tested,’ comments Panmure Gordon’s Dr Julie Simmonds.
The speculation has emerged after Faron said its Traumakine treatment did not produce expected activity seen in previous trials based on early analysis of biomarker indicators.
The company says it is too early to understand why based on early analysis, although the potential causes could include formulation, administration and deactivation.
Simmonds says if Faron can find a legitimate reason for the non-delivery/inactivity of the drug, the underlying potential of Traumakine would be unchanged.
Traumakine aims to treat patients with severe orphan disease Acute Respiratory Disease Syndrome (ARDS), which currently has no approved pharmacological treatment.
Symptoms of ARDS include widespread capillary leakage and inflammation in the lungs after pneumonia, sepsis or significant trauma.
The biopharma company needs to find out what went wrong before determining the next steps as it prepares to undertake further analysis of its data.
A key factor determining what happens next is an ongoing Japanese clinical trial, due to read out in the third quarter of 2018. Even if this is successful, at least one more trial is necessary before Traumakine can reach the market.
Thank you again Gimmiesunshine for all of this valuable information it is very much appreciated.
Clueless.
Unfortunately all I can’t see much details at all being released on FLFL until they’ve bought their extra 5%. They’ve probably got an agreement with Koovs because you would like to think once the plan is out in the open then the share price will go up and FLFL want it to be kept as low as possible for their final buy in. Patience is key on this one and I’m sure we will be very rewarded in the long run.
Thanks Gimmesunshine this is valuable information and much appreciated you sharing us with your findings.
In today’s RNS it was noted that HT Media tranches would be once a year, which we already knew. What I thought was quite interesting was that Koovs said “if required” therefore if sales substantially increase maybe they won’t take HT Media up on their offer of marketing every year and save further share dilution. That could be the reason why they changed it from every 6 months for 2 years to once a year for 4 years to enable Koovs to take a view if we require more advertising and marketing.
I can’t see any big sells today therefore has the big seller finally ran dry and out the game?